Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
This book describes translational cancer therapeutics and the way forward from clinical and molecular diagnosis to treatment. In addition, genomics alterations, microRNAs, and long non-coding RNAs translate precision medicine for the individualistic therapy of cancer patients. It describes the involvement of various pharmacogenetic factors in pharmacodynamic/pharmacokinetic (PD/PK) modulations of medicines. Indeed, the role of bioinformatics and biostatistics, considering the extensive data analysis serving precision medicine approaches, has also been entertained in the present book.…mehr
This book describes translational cancer therapeutics and the way forward from clinical and molecular diagnosis to treatment. In addition, genomics alterations, microRNAs, and long non-coding RNAs translate precision medicine for the individualistic therapy of cancer patients. It describes the involvement of various pharmacogenetic factors in pharmacodynamic/pharmacokinetic (PD/PK) modulations of medicines. Indeed, the role of bioinformatics and biostatistics, considering the extensive data analysis serving precision medicine approaches, has also been entertained in the present book. Therefore, intended book demonstrates the successful medical evidence for the use of precision medicine in the treatment of cancer and its future clinical perspectives. It fills the gaps in cancer biology and precision medicine with its up-to-date content and well-designed chapters. It will serve as a valuable resource for science, medical students, and interdisciplinary researchers. It is a very welcome addition for the scientific community, research centers, and university-industry research collaborators to find out a complete capsular package about cancer drug targets, precision, and personalized medicine (including an introduction to cancer cell signaling, genomic alterations, miRNA targeting, pharmacogenetics, biomarkers, and metabolomics in precision medicine, etc.) at a single platform.
Dr. Hardeep Singh Tuli is an assistant professor at the Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana, India. His research interests focus on the isolation, characterization, and biochemical evaluation of natural metabolites as anticancer agents. He has served as a reviewer for several international journals and as a guest editor for Frontiers in Pharmacology. He has more than ten years of teaching and research experience in pharmacology, mammalian physiology, and natural products. He has published more than 100 papers in peer-reviewed international journals and authored several book chapters. He edited six international books in the area of cancer biology and chemoprevention. Dr. Tuli is an editorial board member of various national and international scientific research journals. In addition, he is in the top 2% of highly cited research in pharmacology.
Prof. Dr. M. Betül Yerer Aycan is working as the Deanof the Faculty of Pharmacy at Erciyes University and as the Director of the Erciyes University Pharmaceutical Application and Research Center accrediting the Pharmaceutical Application and Research Center in eight different categories. Prof. Dr. M. Betül Aycan has more than 100 publications, more than 70 of which are SCI, on the use of natural compounds in neuropsychopharmacology and cancer research, many international book/book chapters, and national and international awards.
Inhaltsangabe
Chapter 1 Evolution of translational cancer therapeutics.- Chapter 2 Oncology: Way forward from clinical and molecular diagnosis to treatment.- Chapter 3 Oncogenic genomics alterations in cancer patient.- Chapter 4 Altered mRNA expression profiles in cancer patients.- Chapter 5 microRNAs and long non-coding RNAs as key targets.- Chapter 6 Oncogenic alterations translated into diagnostics.- Chapter 7 Precision medicine in oncology.- Chapter 8 Precision medicine – translation of individualistic treatment in oncology.- Chapter 9Pharmacogenetics and Pharmacogenomics in Precision Medicine.- Chapter 10 Pharmacogenetic factors in pharmacodynamic/pharmacokinetic (PD/PK) modulations of medicines.- Chapter 11 Biomarkers in Precision Medicine in oncology.- Chapter 12 Bioinformatics and biostatistics in Precision Medicine.- Chapter 13 Omics in Precision medicine.- Chapter 14 Translational therapeutic targets : from bench to clinical trials.- Chapter 15 Strength of integartive genomic alterations, precision medicine and therapeutic targets as treatment choice in patient care.
Chapter 1 Evolution of translational cancer therapeutics.- Chapter 2 Oncology: Way forward from clinical and molecular diagnosis to treatment.- Chapter 3 Oncogenic genomics alterations in cancer patient.- Chapter 4 Altered mRNA expression profiles in cancer patients.- Chapter 5 microRNAs and long non-coding RNAs as key targets.- Chapter 6 Oncogenic alterations translated into diagnostics.- Chapter 7 Precision medicine in oncology.- Chapter 8 Precision medicine - translation of individualistic treatment in oncology.- Chapter 9Pharmacogenetics and Pharmacogenomics in Precision Medicine.- Chapter 10 Pharmacogenetic factors in pharmacodynamic/pharmacokinetic (PD/PK) modulations of medicines.- Chapter 11 Biomarkers in Precision Medicine in oncology.- Chapter 12 Bioinformatics and biostatistics in Precision Medicine.- Chapter 13 Omics in Precision medicine.- Chapter 14 Translational therapeutic targets : from bench to clinical trials.- Chapter 15 Strength of integartive genomic alterations, precision medicine and therapeutic targets as treatment choice in patient care.
Chapter 1 Evolution of translational cancer therapeutics.- Chapter 2 Oncology: Way forward from clinical and molecular diagnosis to treatment.- Chapter 3 Oncogenic genomics alterations in cancer patient.- Chapter 4 Altered mRNA expression profiles in cancer patients.- Chapter 5 microRNAs and long non-coding RNAs as key targets.- Chapter 6 Oncogenic alterations translated into diagnostics.- Chapter 7 Precision medicine in oncology.- Chapter 8 Precision medicine – translation of individualistic treatment in oncology.- Chapter 9Pharmacogenetics and Pharmacogenomics in Precision Medicine.- Chapter 10 Pharmacogenetic factors in pharmacodynamic/pharmacokinetic (PD/PK) modulations of medicines.- Chapter 11 Biomarkers in Precision Medicine in oncology.- Chapter 12 Bioinformatics and biostatistics in Precision Medicine.- Chapter 13 Omics in Precision medicine.- Chapter 14 Translational therapeutic targets : from bench to clinical trials.- Chapter 15 Strength of integartive genomic alterations, precision medicine and therapeutic targets as treatment choice in patient care.
Chapter 1 Evolution of translational cancer therapeutics.- Chapter 2 Oncology: Way forward from clinical and molecular diagnosis to treatment.- Chapter 3 Oncogenic genomics alterations in cancer patient.- Chapter 4 Altered mRNA expression profiles in cancer patients.- Chapter 5 microRNAs and long non-coding RNAs as key targets.- Chapter 6 Oncogenic alterations translated into diagnostics.- Chapter 7 Precision medicine in oncology.- Chapter 8 Precision medicine - translation of individualistic treatment in oncology.- Chapter 9Pharmacogenetics and Pharmacogenomics in Precision Medicine.- Chapter 10 Pharmacogenetic factors in pharmacodynamic/pharmacokinetic (PD/PK) modulations of medicines.- Chapter 11 Biomarkers in Precision Medicine in oncology.- Chapter 12 Bioinformatics and biostatistics in Precision Medicine.- Chapter 13 Omics in Precision medicine.- Chapter 14 Translational therapeutic targets : from bench to clinical trials.- Chapter 15 Strength of integartive genomic alterations, precision medicine and therapeutic targets as treatment choice in patient care.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497